Non-interventional study about the tolerability and efficacy of chemotherapy with Oxaliplatin (Euroxaliplatin(R)) in everday use for treatment of the colorectal carcinoma

Non-interventional study about the tolerability and efficacy of chemotherapy with Oxaliplatin (Euroxaliplatin(R)) in everday use for treatment of the colorectal carcinoma - ABC-Study/002

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00005456

Enrollment

500

Registered

2014-01-07

Start date

2013-11-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colorectal carcinoma C18 C19 C20

Interventions

Group 1: Use of Euroxaliplatin in combination with 5-Fluorouracil und Folinsäure

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: • Histologically confirmed colorectal carcinoma • Age: = 18 years • Signed informed consent • Capacity of the patient to consent (knowledge of manner, significance and consequences of medical operations) • Adequate pregnancy prevention measures during the cytostatic therapy • Therapy in an oncological doctors practice

Exclusion criteria

Exclusion criteria: • Pregnancy (in female patients) • Period of lactation (in female patients)

Design outcomes

Primary

Measure	Time frame
Impact of age, BMI and comorbidity on therapy and tolerability (CTC-checklist version 4.0), effectiveness (objective response rate)	—

Secondary

Measure	Time frame
Progression Free Survival (PFS), impact of physical activity (questions as listed in the eCRF)	—

Countries

Germany

Contacts

Public ContactAnne-Katrin Ullner

OnkoDataMed GmbH

info@onkodatamed.de03342/42689-10

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026